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Background: Hemodialysis services in Vietnam are being decentralised outside of tertiary hospitals. To identify the
challenges to infection control standards for the prevention of bloodborne infections including hepatitis B virus
(HBV) and hepatitis C virus (HCV) we tested the magnitude of HBV and HCV infections in the largest unit in Ho Chi
Minh City servicing patients with end stage renal disease.
Methods: All 113 patients provided consent HBV surface antigen (HBsAg) and HCV core antigen (HCV-coreAg)
testing. Positive patients were tested for viral genotypes. All participants completed a questionnaire on
demographic characteristics, risk factors and previous attendance to other hemodialysis units.
Results: Seroprevalence of 113 patients enrolled was 7% (8/113, 95% CI 2.3%-11.8%) HBsAg, 6% (7/113, 95% CI
1.7%-10.6%) HCV-coreAg and 1% (1/113, 95% CI 0.8%-2.6%) co-infection. Having a HBV positive sexual partner
significantly increased the risk of acquiring HBV (P = 0.016, Odds Ratio (OR) =29, 95% CI 2–365). Risk factors for HCV
included blood transfusion (P = 0.049), multiple visits to different hemodialysis units (P = 0.048, OR = 5.7, 95% CI
1.2–27.5), frequency of hemodialysis (P = 0.029) and AST plasma levels >40 IU/L (P = 0.020, OR = 19.8, 95% CI
2.3–171). On multivariate analysis only blood transfusion remained significant risk factor for HCV (P = 0.027, adjusted
OR = 1.2).
Conclusions: HCV screening for HCV of blood products must improve to meet the infection prevention challenges
of decentralizing hemodialysis services. The level of HCV and HBV in our hemodialysis unit is a warning that
universal precautions will be the next challenge for decentralised hemodialysis services in Vietnam.
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Hemodialysis is routinely used as renal replacement ther-
apy for end stage renal disease (ESRD) patients [1]. In
2012, 2.1 million patients worldwide were estimated to
require hemodialysis and this number is expected to in-
crease by 7% annually [2]. Chronic hemodialysis patients
are at increased risk for both HCV and HBV infections
associated with contaminated blood and blood product
transfusion and exposure to contaminated hemodialysis* Correspondence: m.mclaws@unsw.edu.au
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unless otherwise stated.equipment during treatment [3-6]. Like the community,
chronic hemodialysis patients may also acquire HBV and
HCV through other at-risk activities, such as unprotected
sexual contact and injecting drug use [7,8]. Several in-
fection prevention strategies that are effective in reducing
the acquisition of bloodborne virus by patients in high
resourced healthcare settings includes erythropoiesis-
stimulating agents which has reduced the need of blood
transfusion, HBV vaccination and the adherence by
hemodialysis services to specific hemodialysis infection
control guidelines [9].
In 1983 Vietnam commenced its hemodialysis services
at tertiary hospitals for ESRD patients [10]. In Vietnam 6This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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been estimated to be diagnosed with chronic kidney
disease [11]. Of these 6 million patients 80,000 (1.3%)
patients have already reached ESRD. Currently, the
healthcare system in Vietnam can only provide treatment
to 8,000 (10%) of patients with ESRD. Further, 8,000
patients will be newly diagnosed annually of whom 104
(1.3%) will also go onto require hemodialysis services of
who 10 will receive hemodialyis [11]. To address the
growing demand for hemodialysis, health services will be
decentralised out of tertiary hospitals and become provin-
cial services. Routine universal precautions and infection
control practices for the prevention of bloodborne infec-
tions need to be established to protect the growing num-
ber of ESRD patients from further morbidity. Our study
hemodialysis unit was the first decentralised district unit
established in Ho Chi Minh City in Southern Vietnam in
2009. Since 2009 a further seven units now offer services
to an average of 60–70 patients. We report our preli-
minary findings of the point seroprevalence, risk factors
and genotype of HBV and HCV in newly admitted ESRD
patients.
Methods
Design of the study
In the period between October 2012 and January 2013
all patients aged 18 years and older, newly admitted at
the Hemodialysis Unit, District-6 Hospital, Ho Chi Minh
City, Vietnam were enrolled to participate at the study.
The study protocol was approved by the Human Research
Ethics Committee at UNSW Australia (approval number
HC12363), the Ho Chi Minh City Health Service and
District-6 Hospital authorities.
Participants completed a self-administered question-
naire that comprised of demographics (age and sex), risk
factors that included unprotected sexual contact, injecting
drug use, barber use of razor blade shaving, piercings,
tattooing, blood and blood product transfusions, and at-
tendance to different hemodialysis units. Participants
provided location, name of the hemodialysis unit and
the year of admission so that the data for the number of
different hemodialysis unit visits could be assessed as a
risk factor. Assistance with the questionnaire was pro-
vided when needed by one investigator. Participants
consented to HBV and HCV serology testing, viral geno-
typing. Aminotransaminases (AST and ALT), y-glutamyl
transpeptidase (GGT), medical and dialysis information
were obtained from patients’ medical records. Dialysis
information included: history of blood transfusion,
surgery, abnormal liver function, duration (in months)
of having hemodialysis services, frequency (in days) of
hemodialysis treatments, number of different hemodialysis
units admitted for hemodialysis services and dialyzer
reuse.To validate the information of self-reported transfusion
history all medical records were reviewed for accuracy. Pa-
tients who reported a blood transfusion prior to admission
to the unit were asked to provide the year, place of trans-
fusion and the number of transfusion sessions.
HBV vaccination of new patients is currently not rou-
tinely practiced. Patients are encouraged to have HBV
vaccination at their own cost. None of our patients is
vaccinated. Financial constraint means it is common
practice in Vietnam to reuse dialyzers. Used dialyzers
are labeled with the patient’s name. Used dialyzers for
each patient, regardless of infection status, are cleaned
and stored separately for reuse by the original identified
patient. Given the unavailability of dedicated room for
HBV or HCV infected persons, the study unit has desig-
nated machine for HCV or HBV infected patients. The
unit plans weekly dialysis schedules according to patient
availability and by infection status. Infected patients are
always planned to receive their treatments at less
crowded dialysis sessions. Patients are required to follow
their dialysis schedules so they receive treatment at a
given dedicated dialysis machine at a fixed time.
Laboratory tests
Serum samples obtained by centrifugation of blood
samples at 3,000 g for 10 minutes were stored at −20°C
prior to testing. The ARCHITECT HCV Ag assay
(ABBOTT Laboratories) which is a Chemiluminescent
Microparticle Immunoassay (CMIA) was used to de-
tect HCV-coreAg [12,13]. The ARCHITECT HBsAg
assay (ABBOTT Laboratories), another CMIA, was used
to detect the presence of HBsAg [14]. Positive samples
using these assays were tested for HBV and HCV genotype
by TRUGENE HBV Genotyping kit [15] and TRUGENE
HCV 5′NC Genotyping kit (SIEMENS) [16,17] respect-
ively. Immunoassays did not require sample processing.
For HBV genotyping, DNA from serum samples extracted
by MagNAPure LC instrument (Roche Diagnostics) was
amplified before performing Crosslinking and immu-
noprecipitation (CLIP) sequencing to obtain the query
sequence in accordance with the manufacturer’s protocol.
Genotype was identified by comparing the query sequence
to the HBV genotype consensus sequences of the Open-
Gene system software. For HCV genotyping, a 244-base
pair sequence in the 5′non-coding region of HCV RNA
extracted by MagNAPure LC instrument (Roche Diagnos-
tics) was amplified before performing bidirectional CLIP
sequencing to obtain the sequencing products. These
segments were then detected using the OpenGene DNA
Sequencing System. The forward and reverse sequences
were combined to form a query sequence. Genotype was
identified by comparing the query sequence to the previ-
ously characterized isolates in the Trugene HCV 5′NC
Molecule of the OpenGene system software.
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Data were managed and analysed using Statistical Package
for the Social Sciences (SPSS) version 20 (IBM). Fisher’s
Exact test was used to analyse the significant relationships
between categorical data and Mann–Whitney U test was
used for the comparison of continuous data. Correlations
were used to test for the strength of association between
continuous variables. A multinomial logistic regression
(MLR) model was used to test risk factors for HCV sero-
conversion. Independent variables were entered into the
model and included quantity of blood transfusion, number
of different hemodialysis units admitted for treatment,
the frequency of hemodialysis treatments, duration of
hemodialysis, and AST >40 IU/L. A HBV seroconversion
model to identify significant risk factors could not be built.
Alpha was set at 5% level.
Results
Predisposing factors
113 participants attended the clinic during the 4 months
of enrolment. The mean age of participants was 53 years
(SD ± 16 years, range 18–86 years) (Table 1). Just over half
(52%) of the participants were female and most (98%)
reused dialyzers. The mean duration of hemodialysis was
36 months (SD ± 43 months, range 1.8–245.5 months).
The mean number of hemodialysis treatments was
391 (SD ± 489, range 7–2946 events) and 99% (112/
113) were documented to have received treatment at
other hemodialysis units. Over half (65%, 73/113) of
all patients had received a blood transfusion. Causes
of ESRD included hypertension (31%, 35/113), type-2
diabetes mellitus (30.1%, 34/113), glomerulonephritis
(21.2%, 24/113), obstructive nephropathy plus interstitialTable 1 Patient demographics and clinical characteristics
Female % (n/N) 52 (59/113)
Age (years)
Median [LQ; UQ] 54 [40; 64]
(Mean ± SD) (53 ± 16)
Range 18–86
Duration of hemodialysis (months)
Median [LQ; UQ] 18 [10; 38]
(Mean ± SD) (36 ± 43)
Range 1.8–245.5
Frequency of hemodialysis treatments (days)
Median [LQ; UQ] 195 [87; 441]
(Mean ± SD) (391 ± 489)
Range 7–2946
Patients reusing dialyzer % (n/N) 98 (111/113)
Patients previously having blood transfusion % (n/N) 65 (73/113)
Patients having different hemodialysis unit visits % (n/N) 99 (112/113)kidney disease (3.5%, 4/113) and unknown cause (2.7%,
3/113) (Figure 1).
Seroprevalence and genotyping
Most patients (86%, 95% CI 79.4%-92.2%, 97/113) were
negative for both HBsAg and HCV-coreAg, 7% (95% CI
2.3%-11.8%, 8/113) were HBsAg positive, 6% (95% CI
1.7%-10.6%, 7/113) were HCV-coreAg positive and 1%
(95% CI 0.8%-2.6%,1/113) was HBsAg and HCV-coreAg
positive. The viral genotype distribution among patients
who were HCV-coreAg positive was 1b (3 patients), 1a
(2 patients) and 6a (1 patient) and 2 patients who were
HCV-coreAg positive with untypable virus. There were
5 patients with HBV genotype B and 4 patients who
were HBsAg positive with untypable virus.
Risk factors for HCV infection
Five risk factors (unprotected sexual contact, injecting
drug use, barber use of razor blade shaving, piercings
and tattooing) were not significantly associated with HBV
or HCV.
None of the HCV positive patients reported to have
HCV-positive sexual partner (Table 2). Patients who
were HCV positive were significantly more likely have
received at least one blood transfusion (P = 0.049) and sig-
nificantly more likely (P = 0.048, OR 5.7, 95% CI 1.2-27.5)
to have visited more than two different hemodialysis units
compared with HCV negative patients. The amount of
blood unit transfused was found to be significantly corre-
lated with duration of hemodialysis (r = 0.33, p < 0.01).
HCV positive patients had significantly more hemodialysis
treatments than HCV negative patients (949 vs 348,
P = 0.029) (Table 3). The duration of hemodialysis was
not a significant risk factor (P = 0.068).
Risk factors for HBV infection
Patients with HBV positive sexual partners were sig-
nificantly more likely (P = 0.016, OR 29.0, 95% CI 2.0-
365.0) to be HBV positive compared HBV negative
patients (Table 2). Visiting more than two different
hemodialysis units (P = 1.0), duration of hemodialysis
treatment (P = 0.351) (Table 3) and the frequency of
hemodialysis treatments (P = 0.284) were not a risk factor
for HBV infection.
Association between AST, ALT and GGT and HBV and HCV
infections
After removing potential risk factors (cirrhosis, alcohol
and herbal consumption) that can increase liver enzyme,
ALT, AST and GGT >40 IU/L were observed in 3%
(3/113), 4% (4/113) and 23% (25/113) of study partici-
pants respectively. AST >40 was associated with HCV
positivity (P = 0.02, OR 19.8, 95% CI 2.3-171) while
ALT >40 (P = 0.18) and GGT >40 (P = 0.35) were not.
Figure 1 Etiologies of end stage renal disease on admission.
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HBV positivity (P > 0.05).
Model for the prediction of seroconversion
No other predictor for HCV seroconversion was identi-
fied other than the number of blood transfusion (AOR
1.16, 95% CI 1.01-1.33, P = 0.027) (Table 4).
Discussion
The seroprevalence in hemodialysis patients in Western
countries ranges from 5%-10% for HCV and 0%-6.6% for
HBV [9,18]. The seroprevalence rates in our patients
were similar at 6% for HCV and 7% for HBV. Anti-HCV
and HBsAg assays are the usual method for screening
blood donors in Southern Vietnam where our study was
conducted. The HCV screening rate in Southern Vietnam
blood donors is reported at 0.8%, 7.5 times smaller than
the rate in our patients and the HBV screening rate in
donors, 3.7%, is also less than the rate we found in our
patients [19]. The implementation of infection control
precautions were issued in 1997 in Vietnam [20]. How-
ever, prior to 2001, the prevalence rates for HCV among
chronic hemodialysis patients in tertiary hospitals in HoTable 2 Unadjusted risk factors tested for hepatitis C and hep
Risk factors HCV % (N)
Positive (8) Negative (105) Pa
HBV-positive sexual partners 0 2.8 (3) undeterm
HCV-positive sexual partners 0 1.0 (1) undeterm
At least one blood transfusion 100 (8) 61.9 (65) undeterm
Having >2 different hemodialysis
unit visits
37.5 (3) 9.5 (10) 5.7 (1.2–
aFisher’s Exact Test.Chi Minh City and Hanoi, Vietnam, were hyper-
endemic at 44% to 57% respectively [21,22]. Gradually
awareness of infection control measures for blood trans-
fusion safety increased and screening all blood products
for bloodborne viruses commenced in 2001 [23]. In
2009 the prevalence of HCV in hemodialysis patients
from 5 major cities across Vietnam had reduced but
remained hyper-endemic at 26.6% [24]. A six-year co-
hort study, from 2006 to 2011, in one hemodialysis unit
in Ho Chi Minh City the HCV prevalence of 19.6% (95%
CI 12.4%–15.2%) was three times higher than the preva-
lence in our hemodialysis patient population [25]. Long-
term hemodialysis patients may induce false-negative
results as a result of an unstable immune response in up
to 17.9% of patients tested [26]. We believe the false
negative results in our study will have been negligible as
the specificity of HCV-coreAg assay was 99.8% and the
sensitivity of the assay is equivalent to HCV-RNA assay
[12]. The prevalence for HBV at 4.9% (95% CI 2.2%–
7.2%) [25] and co-infection of HCV and HBV at 2.1%
(95% CI 1.0%–3.3%) [25] from the cohort study were
similar to the rates in our population. Currently, univer-
sal precautions are applied in Vietnam. Yet, our findingsatitis B infections
HBV % (N)
Positive (9) Negative (104) Pa
ined OR 1.0 22.2 (2) 1 (1) 29 (2–365) 0.016
ined OR 1.0 11.1 (1) 0 undetermined OR 0.08
ined OR 0.049 77.8 (7) 63.5 (66) 2.0 (0.4-10.2) 0.5
27.5) 0.048 11.1 (1) 11.5 (12) 1.0 (0.1-8.3) 1.0
Table 3 Association between hemodialysis treatment and HCV and HBV infections
Risk factor HCV (mean ± SD) HBV (mean ± SD)
Positive (N = 8) Negative (N = 105) Pb Positive (N = 9) Negative (N = 104) Pb
Frequency of hemodialysis treatments (days) 949.4 ± 998.5 348 ± 405.5 0.029 366.1 ± 251.9 392.7 ± 504.9 0.284
Duration of hemodialysis (months) 80.1 ± 82.6 32.6 ± 37.2 0.068 32 ± 20 36.3 ± 44.6 0.351
bMann-Whitney U test.
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become routine practice. In addition, seven of our eight
HCV positive patients were transfused after 2001. The
hyper-endemic HCV and HBV in our hemodialysis pa-
tients suggests that poorly screened blood products are
likely to be the source of infection. Besides, age at the
time of acquiring HBV infection is strongly associated
with population endemicity [27]. Vietnam is a high HBV
endemic area [28,29] with perinatal and horizontal
routes still responsible for the majority of transmission
[27].The rate of HBV in our patient population was
similar to other hemodialysis patients in Vietnam sev-
eral years earlier [25] suggesting the risk is stable pos-
sibly due to the high level of community infection
acquired early in life. Hemodialysis patients in Vietnam
would benefit from HBV vaccination prior commencing
hemodialysis treatment.
Blood transfusion is an important risk for HCV infec-
tion among maintenance hemodialysis patients [18]. Our
HCV positive patients were more likely to have acquired
infection from multiple clinics and receiving more than
two blood transfusions. The quality and type of diagnos-
tic test used will impact on the false negative rates mak-
ing comparisons of prevalence infection prevention
strategies between countries and in-country units in-
accurate. The duration of the window period, the time
between the onset of HCV infection and first detection
of antibodies/antigens in the bloodstream, varies with
the most commonly used generation of serology test
from 66 days to only 4 days with the nucleic acid test
(NAT) [30]. The NAT test has greater sensitivity for de-
tecting HCV. Several high resourced countries since
1997 have used NAT as the routine screening test for
blood donors [31]. By 2015 major cities in Vietnam willTable 4 Multinominal logistic regression analysis for
predictors of HCV infections
Risk factors P Adjusted OR (95% CI)
Number of transfused blood (unit) 0.027 1.16 (1.01–1.33)






Duration of hemodialysis (months) 0.36 0.93 (0.74–1.17)
AST >40 (IU/L) 0.13 7.20 (0.65–79.94)use NAT as the screening test for blood donations [32].
We found a modest but significant linear relationship
between blood transfusions and prolonged hemodialysis
treatment (r = 0.33, p <0.01). The decision to transfuse
ESRD patients with anemia is dependent on several indi-
cators, the patient’s age, presence of cardiovascular dis-
eases and severity of anemia symptoms [33]. A third of
our patients were ≥60 of age, 43% had cardiovascular
diseases and a quarter had chronic blood loss due to
gastrointestinal diseases. These indications support re-
peated blood transfusion and the use of erythropoiesis-
stimulating agents. However, one unit of blood transfu-
sion increased the odds for HCV in our patients by 1.16
times. Yet, by strictly complying with a treatment plan,
patients can reduce the risk of anemia that requires
blood transfusions and possible HCV infection. Time on
hemodialysis was not a risk factor for HCV infection in
our study though it was reported elsewhere [18,34]. This
can be explained by the fact that it may not reflect the
true duration of exposure to hemodialysis. Financial
constraints often prevent patients in Vietnam from fol-
lowing their treatment plan. The risk associated with the
frequency of hemodialysis treatments and HCV could
therefore be a proxy for duration.
Challenges for patients having multiple hemodialysis
treatments include repeated vascular access [6] and
potential for exposure to contaminated venous access
devices due to breaches in infection control precautions
[35]. Increased risk for HCV was associated with visits
to multiple hemodialysis units in our study and else-
where [36] which suggests differences in infection control
precautions occur between units. In Vietnam, arterioven-
ous fistula (FAV) operation is not routinely performed
outside a tertiary urban unit. Patients from smaller units
found outside the larger cities, are currently referred to
tertiary units for FAV operation. During their admission
for FAV the patient will receive hemodialysis. Nearly all
our patients had visited at least two other hemodialysis
units. Smaller units may one day provide FAV surgery to
reduce the cost and inconvenience to patients who are
forced to be referred to units in the city. But the practice
of universal precautions will need to be routinely applied
to prevent surgery-associated infections.
HCV genotypes and subtypes are geographically diverse
[37,38]. In Vietnam, type 1b and 6a are the predominant
genotypes [39,40]. Among the typable infections in our
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1a and 6a. Sixty-four chronic hemodialysis HCV infected
patients from Northern Vietnam in 2008 were found to
have a similar genotype distribution with predominance of
genotype 1 [41]. But the real-time RT-PCR technique used
in this study prevented the HCV subtype from being iden-
tified. Among the typable HBV infections, the most com-
mon genotype was B concurring with reports from other
patient sources in Vietnam [42,43].
Increased transaminase levels are associated with
HCV infection [44]. However, elevation of transaminases
(>40 IU/L) is not always present in chronic hemodialysis
patients with viral hepatitis [45]. We found that AST >40
was significantly associated with HCV infection. This sug-
gests that an unexplained or slight increase in AST could
be used to signal early HCV seroconversion. We did not
find an association between increased transaminases and
HBV infection.
Conclusions
The challenge for Vietnam as it rolls out hemodialysis
units from teaching hospitals into smaller centers will be
the faultless routine application of universal precautions,
early HBV vaccination and stringent screening of blood
products countrywide.
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